About the Frederick National Laboratory for Cancer ResearchThe Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) operated by SAIC-Frederick, Inc. for the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). FNLCR is a government-owned, contractor-operated facility, one of the nation's 39 FFRDC's and the only one devoted exclusively to biomedical research and development.
FFRDC CapabilitiesFrederick National Lab provides quick response capabilities and meets special long-term research and development needs for NCI that cannot be met as effectively by existing in-house or contractor resources. The FFRDC also supports other institutes of NIH and wide range of research collaborations and partnerships with third parties, consistent with NCI's mission.
The Frederick National Laboratory conducts basic, translational, and preclinical research and development in cancer and AIDS. FNLCR investigators and technical staff collaborate with other government agencies, academic institutions, life-science companies, and nonprofit research organizations to develop the next generation of tests and treatments that will benefit families affected by cancer.
The lab has established a program through which outside organizations -- including life science companies and other commercial entities -- can enter directly into cooperative research and development agreements with SAIC-Frederick. These agreements can accommodate the development of new technologies for research, or for clinical applications that benefit patients. Under the agreements, partners can have first option to exclusive or nonexclusive commercial license.
The Frederick National Lab offers education, training, and professional development, as well as expert consultation in quality control, regulatory affairs, and patient safety. As a national resource, FNLCR helps biomedical scientists form a solid bridge between basic research and clinical practice, with support that is not readily available elsewhere.